



# PRP ADVISORY

## Presence of Desalkylgidazepam (primary) and Fentanyl/Bromazolam/ Caffeine (co-occurring) detected in a recent Estevan Police seizure

February 9, 2023

### IMPORTANT

The Prescription Review Program (PRP) has been notified by Health Canada's Drug Analysis Service that a benzodiazepine namely, **Desalkylgidazepam** (7-bromo-5-phenyl-1,3-dihydro-2H-benzo[e]1,4]diazepin-2-one) which is under the Controlled Drug and Substances Act (Schedule IV, item 18) was present in a purple powder and/or grainy substance.

Other co-occurring substances were **Fentanyl** (N1(1-phenethyl-4-piperidyl) propionanilide), a benzodiazepine namely, **Bromazolam** (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) and **Caffeine**

The substance was received in Health Canada laboratory on January 11, 2023 and is the first detection of this substance of concern in the Estevan area.

- The substance may also represent a threat to anyone handling it without taking the appropriate health and safety precautions.
- The Drug Analysis Service has instituted a policy to communicate advisories to clients as well as provincial and territorial public health authorities regarding potentially problematic substances. This policy aims to provide information, as part of an early warning system, to warn Canadians of new substances which may pose a potential health hazard.

### QUESTIONS:

For more information, write to the **Prescription Review Program** at [prp@cps.sk.ca](mailto:prp@cps.sk.ca) or call 1-306-244-7355.